ClinicalTrials.gg
TerminatedNCT00927147Updated Jan 31, 2017

Boron Neutron Capture Therapy (BNCT) Combined With Cetuximab in the Treatment of Locally Recurred Head and Neck Cancer

A Phase 1/2 interventional study of BNCT and cetuximab in Head and Neck Cancer, sponsored by Boneca Corporation. Terminated at 1 site in Finland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-31.

Sponsored by Boneca Corporation · Phase 1/2, Interventional, and Treatment

Why this study was terminated
The neutron facility closed down for financial reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 86 studies testing cetuximab in Head and Neck Neoplasms — 2 open to participants now, 7 under way, 2 of them phase 3. Cetuximab · Head and Neck Neoplasms.

Enrollment
63rd of 84
17 · median 37
Started
2009
with 6 others
Phase 1/2
9 of 86
none open now
Registered
40th of 86
by date

Among the 86 studies testing cetuximab in Head and Neck Neoplasms, this one is the 63rd largest by enrollment of the 84 interventional ones that give a count, is one of 7 that started in 2009, is one of 9 in phase 1/2, and was the 40th registered.

Head and Neck Neoplasms

2,714 studies on the registry are indexed under Head and Neck Neoplasms; 596 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

2 of the 86 studies testing cetuximab in Head and Neck Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 453 Head and Neck Neoplasms studies recruiting now, 345 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 21 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing cetuximab in Head and Neck Neoplasms, or all of them as a file.
02

Study summary

The purpose of the study is to investigate efficacy and safety boron neutron capture therapy (BNCT) administered in combination with cetuximab in the treatment of head and neck cancer that has recurred locally following conventional cancer treatment (surgery and radiation therapy). Boron neutron capture therapy is a special form of radiation therapy, which is based on interaction between boron atoms taken up by the cancerous tissue and neutron irradiation. The boron atoms, located within cancer cells, may capture low-energy neutrons obtained from a nuclear accelerator, which results in splitting up (fission) of the boron atoms, and a high radiation effect within the tumor. Cetuximab is an antibody directed against certain proteins found on cancer cell surface (epidermal growth factor receptors). When administered immediately after BNCT, cetuximab may or may not improve treatment efficacy.

Read the detailed description

This is a single-center, non-randomized, non-comparative, open-label, phase I/II trial to determine safety and efficacy of BNCT in the treatment of nonoperable, irradiated, locally advanced cancers of the head and neck region. Patients will be treated with a single-fraction boronophenylalanine (BPA)-based BNCT. All patients will be evaluated for response using CT or magnetic resonance imaging (MRI).

Neutron irradiation will first be planned based on the available tumor imaging examinations, following which the head and body position will be determined for irradiation, and head fixation will be prepared and tested. On the irradiation day 400 mg/m2 L-BPA-F will be infused intravenously over 2 hours. Cetuximab doses will be administered following completion of BNCT. The cetuximab doses will be escalated in cohorts of 3 patients.

03

Conditions studied

  • Head and Neck Cancer

Keywords

  • head and neck cancer
  • boron neutron capture therapy
  • cetuximab
  • epidermal growth factor receptor
  • safety
  • efficacy
  • survival
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed invasive squamous cell carcinoma of the head and neck
  • Inoperable tumor or the patient is not a candidate for surgery for medical reasons; prior surgery may or may not have been done
  • Prior radiotherapy or chemoradiotherapy has been given to the tumor
  • If prior 18F-boronophenylalanine (BPA) PET (positron emission tomography)has been done, BPA needs to accumulate at least 2 times more in the tumor than in the corresponding normal tissue
  • A written

Exclusion criteria

Exclusion Criteria:

  • Presence of distant
  • A non-experimental, effective treatment op-tion is available
  • >3
  • WBC \<2,500/mm3, \<75,000/mm3, serum creatinine >180 umol/L
  • Concomitant systemic cancer chemotherapy (except cetuximab).
  • Other concurrent experimental therapy
  • Less than 1 month since prior radiation therapy
  • Untreated or severe treated congestive heart failure or renal failure
  • A cardiac pace-maker or unremovable metal implants present in the head and neck region that will interfere with MRI-based dose-planning
  • Restlessness or inability to lie in a cast for 30 to 60 minutes
  • Clinical follow-up after therapy cannot be arranged or the patient is not willing to participate in follow-up
  • Pregnancy
  • Age less than 18
  • Known allergy/ to cetuximab
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    BNCT plus cetuximab

    Patients treated with BNCT followed by cetuximab administration

    Radiation: BNCT · Drug: cetuximab

Interventions

  • RadiationBNCT

    Boronophenylalanine infusion followed by neutron irradiation

  • cetuximab infusion 250 to 400 mg/kg intravenously, 1 to 3 infusions

    Also known as: Erbitux

06

What researchers measure

Primary outcomes

  1. Response rate

    Time frame: December 2010

Secondary outcomes

  1. Safety

    Time frame: December 2010

  2. Duration of treatment response

    Time frame: December 2010

  3. Time to progression

    Time frame: December 2010

  4. Survival

    Time frame: December 2010

  5. Adverse events

    Time frame: December 2010

07

Study locations

1 site
  • Department of Oncology, Helsinki University Central Hospital
    Helsinki, FIN-00029, Finland
08

References and documents

Publications

  • Kankaanranta L, Seppala T, Koivunoro H, Saarilahti K, Atula T, Collan J, Salli E, Kortesniemi M, Uusi-Simola J, Makitie A, Seppanen M, Minn H, Kotiluoto P, Auterinen I, Savolainen S, Kouri M, Joensuu H. Boron neutron capture therapy in the treatment of locally recurred head and neck cancer. Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):475-82. doi: 10.1016/j.ijrobp.2007.03.039. Epub 2007 Aug 6. PubMed 17689034 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2009
First posted
Jun 24, 2009
Start
Jun 2009
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Last update
Jan 31, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00927147
Lead sponsor
Boneca Corporation
Responsible party
Sponsor
First posted
Jun 24, 2009
Start date
Jun 2009
Primary completion
Jun 2013
Completion
Jun 2013
Last update
Jan 31, 2017

Study contacts

Heikki Joensuu, MD
study chair · Department of Oncology, Helsinki University Central Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetuximab

Start the discussion